Access Bio, Inc. is launching its CareStart COVID-19 MDx RT-PCR molecular test to detect the SARS CoV-2 virus following receipt of an emergency use authorization (EUA) from the US Food and Drug Administration, the company announced on 23 July.
CareStart COVID-19 MDx RT-PCR detects nucleic acid sequences unique to SARS-CoV-2 that have been extracted, isolated, and purified from nasopharyngeal...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?